system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
1/9/2020 1.90 "Regulatory Exclusivity" means, with respect to any Licensed Product in the Territory, any additional market protection, other than patent protection, granted by a Regulatory Authority in the Territory which confers an exclusive Commercialization period during which Vyera or its Affiliates have the exclusive right to market and sell such Licensed Product in the Field and in the Territory through a regulatory exclusivity right (e.g., new biologic entity exclusivity, new use or indication exclusivity, new formulation exclusivity, orphan drug exclusivity, pediatric exclusivity, or any applicable data exclusivity). 1.91 "Regulatory Materials" means, with respect to the Licensed Product, all documentation, correspondence, submissions and notifications submitted to or received from a Regulatory Authority that are necessary or reasonably useful in order to Commercialize such Licensed Product in the Field in the Territory. For the avoidance of doubt, Regulatory Materials shall include, with respect to each Licensed Product, all Investigational New Drug applications (INDs), BLAs, Regulatory Approvals, and amendments and supplements for any of the foregoing, as well as the contents of any minutes from meetings (whether in person or by audio conference or videoconference) with a Regulatory Authority. 1.92 "Required Third Party License" has the meaning set forth in Section 8.7. 1.93 "Reserved Disputes" has the meaning set forth in Section 12.4. 1.94 "Royalty Term" means the time period beginning with the First Commercial Sale of the Licensed Product in the Territory and continuing until the latest of (a) the expiration of the last Valid Claim Covering the Licensed Product and included in a CytoDyn Patent licensed to Vyera under this Agreement, (b) the date that is ten (10) years from the date of the First Commercial Sale, (c) the expiration of any Regulatory Exclusivity with respect to the Licensed Product and (d) the Biosimilar Entry Date. 1.95 "SBL Agreement" has the meaning set forth in Section 9.2(o). 1.96 "Serious Adverse Event" means any serious untoward medical occurrence in a patient or subject who is administered a Licensed Product, having reference to the provisions of 21 C.F.R 312.32(a), but only if and to the extent that such serious untoward medical occurrence is required under Applicable Laws to be reported to applicable Regulatory Authorities. 1.97 "Sharp Agreement" has the meaning set forth in Section 9.2(o). 1.98 "Side Letter" means that certain letter agreement, dated as of the date hereof, by and between CytoDyn and Vyera. 1.99 "Step-Down Date" means the later of (a) the expiration of the last Valid Claim Covering the Licensed Product and included in a CytoDyn Patent licensed to Vyera under this Agreement and (b) the expiration of any Regulatory Exclusivity with respect to the Licensed Product. 1.100 "Supply Agreement" has the meaning set forth in Section 6.2. 1.101 "Supply Date" has the meaning set forth in Section 11.3(b). Source: CYTODYN INC., 10-Q, 1/9/2020 1.102 "Subsequent Indication" means each indication in the Field other than the Initial Indication, including the Monotherapy Indication; provided that Subsequent Indications must be distinct indications and broadening the use of a Licensed Product for a particular indication shall not be deemed a new indication. By way of illustration, extending the use of the Licensed Product to patients of different age parameters who have multi-drug resistant HIV infection shall not be deemed a new indication distinct from the Initial Indication. For clarity, indications outside of the Field, such as indications in connection with oncology are not included within the scope of this Agreement. 1.103 "Term" has the meaning set forth in Section 11.1. 1.104 "Territory" means the U.S. 1.105 "Third Party" means any Person other than (a) Vyera, (b) CytoDyn or (c) an Affiliate of either of Vyera or CytoDyn. 1.106 "Trademarks" has the meaning set forth in Section 5.4(a). 1.107 "Transition Services" has the meaning set forth in Section 11.7(e)(ii). 1.108 "Transition Services Agreement" has the meaning set forth in Section 11.7(e)(i). 1.109 "U.S." means the United States of America, including its territories and possessions, including Puerto Rico. 1.110 "Valid Claim" means a claim of an issued and unexpired Patent included within the CytoDyn Patents to the extent such claim has not been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent jurisdiction in a final order, from which no further appeal can be taken, and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise. 1.111 "Vyera" has the meaning set forth in the introductory paragraph. 1.112 "Vyera Indemnitee" has the meaning set forth in
"""

Extract the exact clause related to "Third Party Beneficiary" from the excerpt above.

assistant: Not found.